Form 4: LENSAR Director Thomas Ellis Receives Annual Restricted Stock Unit Grant

LENSAR, Inc. Director and 10% owner Thomas B. Ellis was granted 7,374 restricted stock units (RSUs) as part of his annual compensation, aligning his interests with shareholders.

Summary

• Thomas B. Ellis, a Director and 10% owner of LENSAR, Inc. (LNSR), acquired 7,374 restricted stock units (RSUs) on May 23, 2025.
• Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock.
• The RSUs were granted at a price of $0, consistent with their nature as compensation.
• These RSUs will vest in full on May 23, 2026, provided Mr. Ellis continues his service to the Issuer through that date.
• Settlement of the RSUs will occur upon the earliest of Mr. Ellis's termination of service, a change in control of the Company, or his death or disability.
• The grant is part of the Issuer's non-employee director compensation program.
• Following this transaction, Mr. Ellis directly beneficially owns 38,662 shares of common stock.
• Additionally, Mr. Ellis indirectly beneficially owns 1,110,592 shares through North Run Capital, LP, and North Run Advisors, LLC, though he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects a routine, positive event of aligning director incentives with company performance through equity compensation, which is generally viewed favorably by investors as it promotes long-term commitment.

Positives

• The grant of restricted stock units to Director Thomas B. Ellis aligns his financial interests directly with the long-term performance of LENSAR, Inc. and its shareholders.
• The RSU grant is a standard component of the company's non-employee director compensation program, indicating a structured approach to executive incentives.

Risks

• The RSUs are subject to forfeiture if the Reporting Person's service to the Issuer terminates prior to the vesting date of May 23, 2026.
• The value of the RSUs upon vesting is dependent on the future market price of LENSAR, Inc. common stock, introducing market risk.

Future Outlook

The granted restricted stock units are set to vest on May 23, 2026, contingent on the director's continued service, which indicates a future alignment of interests.

Industry Context

The grant of restricted stock units to non-employee directors is a common practice across various industries, particularly in the medical technology and ophthalmology sectors, to attract and retain qualified board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The RSU grant as a component of non-employee director compensation is a standard practice, comparable to compensation structures seen at other publicly traded medical device companies such as Alcon Inc. (ALC) or Carl Zeiss Meditec AG (AFX.DE), which often utilize equity awards to incentivize long-term commitment and performance.
• The vesting schedule tied to continued service is typical for such equity grants, ensuring directors remain engaged with the company's strategic objectives.

Corporate Governance

Related Party Transactions

• Thomas B. Ellis's indirect beneficial ownership of 1,110,592 shares is through North Run Capital, LP, and North Run Advisors, LLC, entities with which he is associated as a member of North Run Advisors, LLC. This represents a disclosed related party interest in the company's securities.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value.
• Management: The compensation structure for directors supports the overall governance framework and incentivizes board oversight.

Next Steps

• The restricted stock units are scheduled to vest on May 23, 2026, subject to continued service.

Key Dates

Keywords

LENSAR, LNSR, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Beneficial Ownership, Equity Grant, Corporate Governance